-
We detected your language preference as English. Would you like to switch to the English version for a better experience?
Switch to English
Stay here
China has formally elevated biomedical innovation within its industrial development agenda with a new five-year pharmaceutical industry plan covering 2026 through 2030. Jointly issued by the Ministry of Industry and Information Technology and other government authorities, the blueprint calls for China's pharmaceutical research, development and application capabilities to remain at the global forefront by the end of the decade.
One of the plan's most visible objectives is to increase China's contribution to original drug innovation. First-in-class drugs developed in China are targeted to represent at least 25% of the global total by 2030. The plan also calls for the innovative-drug sector to maintain average annual growth of more than 20%, indicating that policymakers are targeting not only a larger domestic pharmaceutical industry but also a sustained expansion in innovative medicines.
The industrial targets are similarly substantial. Pharmaceutical enterprises above China's designated scale threshold are expected to generate combined annual revenue of at least 3.5 trillion yuan by 2030. The plan further aims to cultivate 50 pharmaceutical companies with annual revenue exceeding 10 billion yuan and at least five Chinese drug products with global annual sales above $1 billion.
Selected 2030 targets
The policy direction reflects a structural change already visible in China's pharmaceutical sector. For decades, China's global pharmaceutical position was closely associated with active pharmaceutical ingredient manufacturing, a large domestic market and increasingly important contract research and manufacturing capabilities. The new blueprint explicitly seeks to strengthen the next stage: the creation, development and international commercialisation of innovative medicines.
“The plan arrives at a pivotal moment as China's pharmaceutical industry shifts rapidly from its traditional identity as a supplier of active pharmaceutical ingredients and a large consumption market toward a new phase defined by the export of innovative drugs.”
The scale of China's development base provides an important foundation for that transition. According to Chinese government figures, the country had 4,751 innovative drugs in its pipeline at the end of 2025, representing approximately one-third of the global total and placing China first globally by the number of drugs under development. In the first half of 2026, 38 innovative drugs were approved in China, of which 31 were domestically developed.
The new plan therefore places greater emphasis on the quality and originality of the pipeline rather than pipeline volume alone. It identifies 25 priority tasks across eight areas, with objectives spanning original innovation, research infrastructure, industrial capabilities, technology platforms and internationalisation. Frontier areas include AI-assisted drug discovery, gene editing, cell programming, precision molecular delivery, organoids and other emerging biomedical technologies.
The technology priorities outlined in the plan extend well beyond conventional small-molecule pharmaceuticals. Antibody-drug conjugates, cell and gene therapies, CAR-T therapies and next-generation vaccines are among the areas receiving policy attention. AI-driven drug discovery is also positioned as an important component of the country's effort to shorten discovery and development cycles.
Vaccine development is another priority, with newer technology platforms such as mRNA forming part of the industry's intended evolution. Traditional Chinese medicine is included in the blueprint as well, with policymakers seeking to apply modern industrial, research and regulatory frameworks to its development and internationalisation.
The breadth of the technology agenda is significant because it links pharmaceutical innovation with adjacent capabilities in computing, biotechnology, medical devices and advanced manufacturing. The plan also identifies innovative medical devices as a strategic component, with a target of more than 200 innovative devices approved by 2030.
The strategic shift is taking place against a backdrop of rapidly increasing international interest in Chinese biopharmaceutical assets. Global pharmaceutical companies have increasingly turned to Chinese biotechnology companies for access to differentiated clinical programmes, platform technologies and early-stage innovation.
Recent transactions illustrate the changing scale of that activity. In January 2026, AstraZeneca entered an agreement with CSPC Pharmaceutical Group covering multiple obesity and type 2 diabetes programmes. The agreement includes $1.2 billion in upfront consideration and potential development, regulatory, commercialisation and sales-related payments that could bring the total value to as much as $18.5 billion.
In May 2026, Bristol Myers Squibb and Hengrui Pharma announced strategic collaboration and licensing agreements covering 13 early-stage programmes across oncology, hematology and immunology. The agreements have a potential aggregate value of approximately $15.2 billion, including milestone and option payments, while BMS committed up to $950 million in specified upfront and anniversary payments.
These transactions illustrate an important evolution in the China-to-global pharmaceutical relationship: international companies are not simply purchasing individual assets but increasingly accessing development platforms, discovery capabilities and broader portfolios. That model aligns with the government's stated ambition to move beyond licensing and establish Chinese companies as participants across the global pharmaceutical value chain.
The 2030 blueprint explicitly encourages Chinese pharmaceutical companies to deepen their international footprint through overseas research and development, manufacturing, international clinical trials, cross-border technology cooperation and participation in global pharmaceutical supply chains.
This objective is increasingly relevant as the value of overseas licensing involving Chinese innovative medicines expands. Chinese government data indicate that the total value of overseas licensing deals for innovative Chinese drugs had surpassed $120 billion in 2026, up 36% year on year.
The strategic objective is therefore broader than simply increasing the number of assets licensed to multinational pharmaceutical companies. It involves building capabilities that allow Chinese companies to conduct development internationally, manage global clinical programmes, manufacture at international scale and retain greater participation in downstream commercial value.
That expansion will occur within a more complicated geopolitical environment. Chinese life-science companies with substantial international operations continue to face regulatory and national-security scrutiny in the United States. Such considerations can affect investment structures, technology collaboration, supply-chain planning and the geographic allocation of R&D and manufacturing activities.
The pharmaceutical blueprint is part of a larger industrial policy programme rather than a standalone healthcare initiative. Biomedicine has been identified alongside integrated circuits, aerospace, the low-altitude economy, new energy storage and intelligent robotics as one of six emerging pillar industries targeted for strategic development. The combined output of these sectors was nearly 6 trillion yuan in 2025, with a policy objective of exceeding 10 trillion yuan by 2030.
Within pharmaceuticals, the plan also promotes the development of regional industrial clusters, including the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area and the Chengdu-Chongqing region. Additional emphasis is placed on central manufacturing clusters and traditional and ethnic medicine industries.
The combination of national targets, regional clusters and technology-specific priorities indicates an attempt to build an integrated ecosystem rather than relying on a small number of successful drug developers. R&D, clinical development, manufacturing, medical devices, digital technologies and international commercialisation are being treated as connected components of the same industrial strategy.
GuideView analysts observe that the most consequential element of China's 2030 biomedical blueprint is not any individual numerical target, but the attempted transition from pipeline participation to full value-chain participation. China's large clinical-development base and expanding innovative-drug pipeline have already made its biotechnology sector an important source of assets for multinational pharmaceutical companies. The new policy seeks to convert that position into durable domestic capabilities in discovery, development, manufacturing and global commercialisation.
The strategy also reflects a growing convergence between pharmaceutical R&D and computational technologies. AI-enabled discovery, advanced biological modalities and data-intensive development are being incorporated into the industrial policy framework rather than treated as isolated technology experiments. If implementation follows the blueprint, competitive differentiation could increasingly depend on the integration of these capabilities across the drug-development process.
For global pharmaceutical companies, the development creates a market structure in which Chinese companies may increasingly appear not only as licensing counterparties but also as discovery partners, co-development participants, technology-platform providers and potential global competitors. Recent agreements involving AstraZeneca, CSPC, Bristol Myers Squibb and Hengrui demonstrate the commercial relevance of that shift.
GuideView therefore expects the key industry question through 2030 to be how effectively China's policy ambition translates into globally validated medicines, sustained R&D productivity and international commercial presence. The distinction between a large domestic pipeline and a globally competitive innovation ecosystem will ultimately depend on clinical outcomes, regulatory approvals, technology transfer, commercial execution and the ability of Chinese companies to operate across increasingly complex international markets.
The five-year plan was released on September 18, 2026. The policy document was jointly issued by China's Ministry of Industry and Information Technology and other government authorities and forms part of the country's 15th Five-Year Plan period. Government reporting identifies the pharmaceutical industry's 2030 objectives, while corporate announcements provide transaction-level details for recent international collaborations.
GuideView's analysis incorporates the policy targets and recent transaction developments to distinguish the stated objectives of China's pharmaceutical strategy from the market evidence currently visible in global licensing and collaboration activity.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
